Latest News and Press Releases

Zug, Switzerland, August 3, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Closing of asset transfer from Otifex Therapeutics Rights to additional preclinical and clinical data complement scope of data package Initiation of Phase 1 trial of AM-125 planned for the...

Top-line results from the HEALOS trial are expected in the fall of 2017 Zug, Switzerland, July 5, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to...

Zug, Switzerland, June 22, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Program to highlight AM-125 for vertigo and upcoming Phase 3 data readouts for AM-111 and Keyzilen® Featured presentation by Dr. Elias Michaelides, Yale School of Medicine Zug, Switzerland,...

Progressing toward completed enrollment of the AM-111 Phase 3 HEALOS trial Key Opinion Leader event scheduled for June 16 in New York City Conference call set for 8 am ET (2 pm CET) today ...

Trial outcomes provide further evidence for safety of Keyzilen® in chronic intermittent use Exploratory efficacy results suggest potential benefits of repeating treatment cycles    Zug,...

Zug, Switzerland, May 4, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...

Trial outcomes show positive safety profile of Keyzilen® for chronic intermittent use Exploratory efficacy results support therapeutic concept of early tinnitus treatment Zug, Switzerland,...

ZUG, Switzerland, March 31, 2017 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs...